Alflutinib mesylate (formerly also known as AST-2818; AST2818; Furmonertinib), the mesylate salt form of Alflutinib, is a novel, irreversible and 3rd generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) selective for EGFR T790M mutation.
AG555 is a potent epidermal growth factor receptor (EGFR) kinase inhibitor.
Lifirafenib (formerly BGB-283, Beigene-283) is a potent inhibitor of the RAF kinases and EGFR in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
Dacomitinib (aslo known as PF299804, PF299; trade name: Vizimpro) is a novel, potent, orally bioavailable, highly selective, irreversible, second generation pan-ErbB inhibitor, mostly to EGFR with with IC50 of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively in cell-free assays.
Canertinib (formerly also known as CI-1033; CI 1033; PD-183805) is a novel, potent and orally bioavailable quinazoline class of pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.
Theliatinib (formerly HMPL-309; HMPL309; HMPL 309; xiliertinibum; xiliertinib) is a novel and highly potent EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) with potential antitumor and anti-angiogenesis activities.
Genistein (NPI-031L; BIO-300; G-2535; PTI-G-4660; SIPI-9764I), a naturally occuring isoflavonoid isolated from soy products, is a potent multi-kinase inhibitor with potential anticancer activity against various cancers.
Erlotinib (formerly OSI744, trade name: Tarceva) is a quinazoline-based EGFR (epidermal growth factor receptor) inhibitor with potential antineoplastic activity.
Butein (NSC 652892; CCG-208298; CS5675; AC1NQY7L) is a naturally occuring plant polyphenol and chalconoid isolated from Rhus verniciflua with a broad spectrum of pharmacological effects such as antiinflammatory, antioxidative, aldose reductase and advanced glycation endproducts inhibitory and anticancer activities.
AV-412 (AV412; MP-412) is a 2nd generation and orally bioavailable EGFR inhibitor with anticancer activity.